Q-omics provides the consensus-scored TRIM40 profile across patient tissues and cancer cell-line models. TRIM40 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TRIM40 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TRIM40 RNA expression shows 8,444 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUAD, KIRC, and ESCA as cancer lineages where TRIM40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM40 survival associations across molecular data types. TRIM40 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM40 RNA expression–survival associations across cancer types. High TRIM40 expression shows unfavorable associations in LUAD, SARC, TGCT and OV, but favorable associations in ACC and PRAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for TRIM40 RNA expression.
This table summarizes TRIM40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM40 shows lower tumor expression in KIRC, KIRP, COAD, KICH and READ and higher tumor expression in LIHC. The KIRC box plot shows higher TRIM40 RNA expression in normal versus tumor tissue (log2 FC = −0.123, t-test p < 0.001).
This table shows molecular features associated with TRIM40 in patient tissues and cancer cell lines. In patient samples, TRIM40 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM40 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
